Indium 111 Oxyquinolone by is a Prescription medication manufactured, distributed, or labeled by AnazaoHealth Corporation. Drug facts, warnings, and ingredients follow.
This preparation is supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a pH range of 6.5 to 7.5 and is not for direct injection. Each milliliter contains 2 mCi at calibration time, 50μg oxyquinoline, 100μg polysorbate 80, and 6 mg of HEPES (N-2-hydroxyethyl-piperazine-N’-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution. It is intended for single use only and contains no bacteriostatic agent.
Indium forms a saturated (1:3) complex with oxyquinoline. The complex is neutral and lipid-soluble, which enables it to penetrate the cell membrane. Within the cell, indium becomes firmly attached to cytoplasmic components; the liberated oxyquinoline is released by the cell. It is thought that the mechanism of labeling cells with Indium In-111 Oxyquinoline involves an exchange reaction between the oxyquinoline carrier and subcellular components, which chelate indium more strongly than oxyquinoline. The low stability constant of the oxyquinoline complex, estimated at approximately 10, supports this theory.
Following the recommended leukocyte cell labeling procedure, approximately 77% of the added Indium In-111Oxyquinoline is incorporated in the resulting cell pellet (which represents approximately 3-4 x 108 WBC).
Cell clumping can occur and was found in about one fifth of the leukocyte preparations examined. The presence of red blood cells or plasma will lead to reduced leukocyte labeling efficiency. Transferrin in plasma competes for Indium In-111 Oxyquinoline.
Chemotaxis of granulocytes deteriorates during storage and loss of chemotaxis may cause false negative scans. The spontaneous release of Indium In-111 has been reported to range from about 3% at one hour to 24% at 24 hours [ten Berge, R.J.M., Natarajan, A.T., Hardeman, M.R., et al. Labeling with Indium In-111 has detrimental effects on human lymphocytes. Journal of Nuclear Medicine, 24, 615-620 (1983)]. The maximum amount of time recommended between drawing the blood and reinjection should not exceed 5 hours. It is recommended that the labeled cells be used within one hour of preparation, if possible, and no more than three hours after preparation.
Cell aggregates of various degrees have been reported. Cell labeling techniques and standing of cell preparation may be contributing factors.
Strict aseptic techniques should be used to maintain sterility throughout the procedures for using this preparation.
Do not use after the expiration time and date (5 days after calibration) stated on the label. The contents of the vial are radioactive. Adequate shielding of the preparation must be maintained at all times.
Indium In-111 Oxyquinoline, like other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient management. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides
The recommended adult (70kg) dose of Indium In-111 Oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 MBq (200-500 μCi). Indium In-111 Oxyquinoline solution is intended for radiolabeling of autologous leukocytes. The Indium In-111 Oxyquinoline labeled autologous leukocytes are administered intravenously.
Imaging is recommended at approximately 24 hours post injection. Typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required. Aseptic procedures and a shielded syringe should be employed in the withdrawal of Indium In-111 Oxyquinoline from the vial. Similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. The user should wear waterproof gloves during the entire procedure. The patient’s dose should be measured by a suitable radioactivity calibration system immediately before administration. At this time, the leukocyte preparation should be checked for gross clumping and red blood cell contamination
Sterile technique must be used throughout. It is important that all equipment used for the preparation of reagents be thoroughly cleaned to assure the absence of trace metal impurities. The user should wear waterproof gloves during the handling and administration procedure
INDIUM 111 OXYQUINOLONE
indium 111 oxyquinolone solution |
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
Labeler - AnazaoHealth Corporation (011038762) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
AnazaoHealth Corporation | 011038762 | MANUFACTURE |